VVVerna Vanderpuye

Verna Vanderpuye

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Verna Vanderpuye has a total of 345 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The African Cancer Leaders Institute: a decade of strategic development of the African next generation leaders in cancer care, research, education and advocacy

    by Yosr Hamdi, Achille Manirakiza, Gad Murenzi, Violet Kayamba, Nahla Gafer, Prisca Adejumo, Lauren N Singh, Verna Vanderpuye, Paul Ndom, Serigne Magueye, et al.

    Leadership and mentorship play an important role in supporting the career development of health professionals. In many African countries, supervision activities focus on technical and operational aspects rather than catalysing career and leadership development. Thus, mentorship and coaching interventions need to be implemented in African healthcare institutions as components of health systems strengthening strategies. Due to its holistic nature, cancer care involves interprofessional collaborations to develop and provide a problem-solving mindset. It is therefore an area that would benefit from leadership and mentorship, mainly in a limited-resources context. The identified benefits from leadership development in cancer care in Africa led to the creation of the African Cancer Leaders Institute (ACLI) of the African Organization for Research and Training in Cancer (AORTIC), consisting of mentors and trainees from Africa and the USA. ACLI trainees are selected through a competitive application process. During the ACLI biennial meetings, coinciding with the AORTIC conference, trainees, including early-stage/mid-career investigators, oncologists, nurses, advocates and other health professionals, meet to learn about best practices in cancer research, grant writing, scientific reporting, mentor relationships, academic pressures and professional-personal life balance. This paper describes the goals of the ACLI, its mission and achievements, the vision behind creating such important programmes and the benefits of its participants in leadership, coaching and mentorship in improving cancer care in Africa.

  • Targeting Inequities: Addressing Lung Cancer Care Challenges in Africa Through Drug Access, Radiotherapy, and Surgical Innovations

    by Elvis Obomanu, Chidiebube Ugwu, Muluken Megiso, Tarfa Verinumbe, Colton Jones, Verna Vanderpuye, Nazik Hammad

    Lung cancer remains one of the leading causes of cancer-related mortality in Africa, with survival rates starkly lagging behind global benchmarks because of systemic inequities in prevention, diagnosis, and treatment access. Despite representing only 6% of global smokers, the continent faces a disproportionate burden driven by environmental and occupational carcinogens, aggressive tobacco marketing, and fragmented health care infrastructure. Key challenges include prohibitive delays in accessing targeted therapies like epidermal growth factor receptor inhibitors and immunotherapies, a dire shortage of radiotherapy infrastructure-0.12 megavoltage units per million people versus the International Atomic Energy Agency's recommended five megavoltage units per million, and a dearth of thoracic surgeons (0.03 thoracic surgeons per 100,000 people). These barriers contribute to over 90% of patients presenting with advanced-stage disease and 5-year survival rates below 10%. Multifaceted strategies are essential to bridge these gaps: regional pooled procurement and compulsory licensing to lower drug costs, telemedicine platforms like the African Radiation Oncology Network to expand radiotherapy access, and task-shifting surgical training programs through institutions such as The College of Surgeons of East, Central, and Southern Africa, which graduates 15 cardiothoracic specialists annually and partnerships such as that between the West African College of Surgeons and Global Oncology Group at Queens University, Canada. Investments in critical care infrastructure, exemplified by dedicated thoracic intensive care units in Ghana and Kenya, alongside harmonized guidelines from the African Cancer Coalition, are pivotal. The Lancet Oncology Commission underscores the urgency of political commitment and sustainable investment in diagnostics, workforce training, and technology transfer to align Africa's cancer care with global standards. Addressing these inequities is a clinical imperative and a moral obligation to ensure life-saving innovations benefit all populations equitably.

  • Open Access

    Management of epithelial ovarian cancer in sub-Saharan Africa: a survey of practicing physicians

    by Ya Haddy Sallah, Verna Vanderpuye, Rahel Ghebre, Khadija Warfa, Alex Mutombo Baleka, Hannah Naa Gogwe Ayettey Anie, Pa Omadou Sallah, Esayas Berhanu Enoro, Namugga Jane, Rose Anorlu

    The purpose of this study was to evaluate current practices in the management of epithelial ovarian cancer (OC) in sub-Saharan Africa (SSA). A 27-question survey was distributed to SSA-based physicians who managed OC and were members of the African Organisation for Research and Training in Cancer (AORTIC) via Research Electronic Data Capture. Questions evaluated diagnostics, imaging, surgical capacity, guideline adherence, access and barriers to systemic therapies, genetic testing and palliative care. Survey responses from 58 providers in 25 SSA countries were analysed. Clinical/medical oncologists and gynaecologic oncologists made up 52% and 36% of the respondents, respectively. Harmonised guidelines for SSA and the European Society of Medical Oncology guidelines were the most commonly used guidelines among respondents. Surgeries were performed by gynaecologic oncologists (53%) and general gynaecologists (38%). Complete cytoreductive surgery was the primary surgical goal for 38% of the respondents. Lymphadenectomy was routinely performed in 34% of patients with early-stage disease. The majority of systemic therapies were prescribed by clinical/medical oncologists (76%). Platinum/taxane doublet chemotherapy was the prevalent choice for adjuvant (90%) and neoadjuvant indications (83%). Single-agent gemcitabine was preferred for treating platinum-resistant disease (55%). Bevacizumab was prescribed by 33% of the providers. BRCA testing was limited. Drugs that target BRCA-positive tumours were prescribed by 12% of the respondents. Referral to routine palliative care services for advanced disease was performed by 41% of the respondents. The survey results demonstrate areas of guideline-concordant care for OC in SSA despite several challenges, including limited subspecialty surgical capacity and highlight important remaining gaps. To improve OC outcomes in SSA, increasing gynaecologic oncology capacity, promoting and adopting context-specific guidelines and supporting implementation-focused research require prioritisation.

  • Barriers to Breast Cancer Care for Women Presenting at District and Regional-Level Hospitals in Ghana: Findings From the African Breast Cancer-Disparities in Outcomes Ghana Study

    by Clement Tetteh Narh, Maxwell Afetor, Frank Ekow Baiden, Adams Agbeko, Mary Efua Commeh, Lydia Aziato, Isabel Dos-Santos-Silva, Valerie McCormack, Verna Vanderpuye, on behalf of the ABC-DO Ghana team, et al.

    PURPOSE: The WHO Global Breast Cancer Initiative (GBCI) aims to improve breast cancer (BC) survival through early stage at diagnosis, prompt diagnostic evaluation, and appropriate multimodality treatment. Care pathway analysis helps to evaluate delay and dropouts through this process. Little is known about the BC care pathway of women first presenting at lower level of health systems in Africa. METHODS: Between March 2023 and February 2024, we prospectively recruited 243 women age ≥18 years in eight (six district, one regional and teaching) hospitals who, owing to breast symptoms, were referred for breast biopsy in the Oti and Volta regions of Ghana. We determined the percentages of biopsy uptake (study paid if needed), histology results receipt, survival, and treatment initiation and explored how patient-, family-, and health system–related factors influenced care pathways. RESULTS: Of the 243 women referred, 53 (21.1%) did not have biopsy taken for health system–related (n = 22, 41%) and participant-related (n = 26, 59%) reasons. Among 190 women who had a biopsy, 102 (54%) were malignant. The median time from first visit (recruitment) to obtaining biopsy results was 14 days (IQR, 9-27). Among malignant cases, 61% (62/102) were stage III/IV (GBCI pillar 1) and 65 (64%) of 102 initiated treatment (GBCI pillar 3) with a median time from first visit to treatment initiation of 76 days (IQR, 36-131). Thirty-seven (36%) women whose biopsies were malignant did not initiate treatment because of participant-related (19 [51%]) and health system–related (12 [32%]) factors. The 1-year survival was 76% (95% CI, 66 to 84). CONCLUSION: In a unique study of women from lower levels of the health system in Ghana, we observed large gaps in biopsy uptake and treatment access, but excellent pathology turnaround times.


  • Open Access

    Aflatoxin exposure and primary liver cancer in Ghana

    by Yvonne Nartey, Ralph Kwame Akyea, Brian Cox, Verna Vanderpuye

    Liver cancer ranks among the leading causes of cancer-related deaths globally, with over 700 000 deaths reported in 2022. 1 The incidence of liver cancer is particularly high in low- and middle-income countries (LMICs), primarily in sub-Saharan Africa and Southeast Asia.1 In 2022, an estimated 866 136 new cases of primary liver cancer were reported worldwide, highlighting its prevalence as one of the most common cancers globally.1 The incidence of liver cancer and related mortality rates are projected to increase between 2020 and 2040, new cases are expected to rise by 55%, with mortality rising by 56.4%.2 These alarming trends underscore the need to better understand the risk factors driving the rise in liver cancer cases, particularly in regions like Ghana where multiple risk factors converge. In Ghana, an estimated 3731 people were newly diagnosed with liver cancer in 2022 and 3362 died from the disease.1


  • Open Access

    Medical Tourism for Cancer Treatment: Trends, Trajectories, and Perspectives From African Countries

    by Fidel Rubagumya, Laura Carson, Daniel Afolayan, Eulade Rugengamanzi, Godwin Abdiel Nnko, Omar Abdihamid, Verna Vanderpuye, Nazik Hammad

    PURPOSE: Cancer continues to be a significant public health concern. Sub-Saharan Africa (SSA) struggles with a lack of proper infrastructure and adequate cancer care workforce. This has led to some countries relying on referrals of cancer care to countries with higher income levels. In some instances, patients refer themselves. Some countries have made it their goal to attract patients from other countries, a term that has been referred to as medical tourism. In this article, we explore the current status of oncology-related medical tourism in SSA. METHODS: This was a cross-sectional study. The study participants included oncologists, surgeons, and any other physicians who take care of patients with cancer. A predesigned questionnaire was distributed through African Organization for Research and Training in Cancer member mailing list and through study team personal contacts and social media. RESULTS: A total of 52 participants from 17 African countries with a 1.6:2 male to female ratio responded to the survey. Most (55.8%) of the respondents were from Eastern African countries. The majority (92%) of study participants reported that they knew patients who referred themselves abroad, whereas 75% referred patients abroad, and the most common (94%) referral destination was India. The most common (93%) reason for referral was perception of a higher quality of care in foreign health institutions. CONCLUSION: The findings suggest the need to improve local health care systems including building trust of the system among general population. The study highlights potential financial toxicity, and it adds to the current emphasis on return of investment on homegrown workforce and cancer treatment infrastructure.


  • Prevalence of Preferences for End-of-Life Place of Care and Death Among Patients With Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis

    by Andrew Donkor, Prince Nyansah Adotey, Esther Oparebea Ofori, Jennifer Akyen Ayitey, Caleb Ferguson, Tim Luckett, Verna Vanderpuye, Ernest Baawuah Osei–Bonsu, Caroline Phelan, Katherine Hunt

    PURPOSE: There is limited information on preferences for place of care and death among patients with cancer in low- and middle-income countries (LMICs). The aim was to report the prevalence and determinants of preferences for end-of-life place of care and death among patients with cancer in LMICs and identify concordance between the preferred and actual place of death. METHODS: Systematic review and meta-analysis guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses was conducted. Four electronic databases were searched to identify studies of any design that reported on the preferred and actual place of care and death of patients with cancer in LMICs. A random-effects meta-analysis estimated pooled prevalences, with 95% CI, with subgroup analyses for region and risk of bias. RESULTS: Thirteen studies were included. Of 3,837 patients with cancer, 62% (95% CI, 49 to 75) preferred to die at home; however, the prevalence of actual home death was 37% (95% CI, 13 to 60). Subgroup analyses found that preferences for home as place of death varied from 55% (95% CI, 41 to 69) for Asia to 64% (95% CI, 57 to 71) for South America and 72% (95% CI, 48 to 97) for Africa. The concordance between the preferred and actual place of death was 48% (95% CI, 41 to 55) for South Africa and 92% (95% CI, 88 to 95) for Malaysia. Factors associated with an increased likelihood of preferred home death included performance status and patients with breast cancer. CONCLUSION: There is very little literature from LMICs on the preferences for end-of-life place of care and death among patients with cancer. Rigorous research is needed to help understand how preferences of patients with cancer change during their journey through cancer.


  • Open Access

    Global Equity in Clinical Trials: An ASCO Policy Statement

    by Sana A. Al Sukhun, Verna Vanderpuye, Carolyn Taylor, Abiola Falilat Ibraheem, Andres Wiernik Rodriguez, Fredrick Chite Asirwa, Michael Francisco, Allyn Moushey

    ASCO is a global professional society representing more than 50,000 physicians, other health care professionals, and advocates in over 100 countries specializing in cancer treatment, diagnosis, prevention, and advocacy. ASCO strives, through research, education, and promotion of the highest quality of patient care, to create a world where cancer is prevented or cured, and every survivor is healthy. In this pursuit, health equity remains the guiding institutional principle that applies to all its activities across the cancer care continuum. This ASCO policy statement emphasizes the urgent need for global equity in clinical trials, aiming to enhance access and representation in cancer research as it not only improves cancer outcomes but also upholds principles of fairness and justice in health care.


  • Open Access

    Expanding Access to Computed Tomographic Staging and Three-Dimensional Intensity Modulated Radiotherapy for Cervical Cancer in Ghana

    by Aba Anoa Scott, Verna Vanderpuye, Mary-Ann Dadzie, Joel Yarney, Charles Akoto Aidoo, Judith Tackie, Stephen Kpatsi, Samuel Boateng, Tony Obeng-Mensah, Michael Nyamadi, et al.

    PURPOSE: To build capacity for improved treatment of locally advanced cervical cancer in Ghana, including computed tomography (CT) staging and intensity modulated radiotherapy (IMRT). MATERIALS AND METHODS: Patients with histologically confirmed cervical cancer were prospectively staged with abdominopelvic CT and ultrasound and offered the opportunity to have IMRT instead of conventional two-dimensional radiotherapy. The development of an efficient, high-quality, and safe IMRT program was facilitated by investment in new technology and comprehensive training of the interdisciplinary radiotherapy team in collaboration with a North American center of excellence. RESULTS: Of 215 patients with cervical cancer referred in 2022, 66% were able to afford CT scans and 26% were able to afford IMRT. Lymph node metastases were identified in 52% of patients by CT but in only 2% of patients by ultrasound. The use of CT resulted in 63% of patients being upstaged and changed treatment intent or radiation treatment volumes in 67% of patients. Patients who had IMRT experienced fewer acute side effects and were more likely to complete treatment as planned. CONCLUSION: It is feasible to provide state-of the-art cancer treatment with CT staging and IMRT to patients with cervical cancer in low-resource settings and achieve meaningful improvements in outcomes. It requires a broad commitment by program leadership to invest in technology and staff training. Major challenges include balancing improved clinical care with reduced patient throughput when radiation treatment capacity is constrained, and with the additional cost in the absence of universal health coverage.